Hemogenyx Pharmaceuticals Share Discussion Threads

[porky9] 18/10/2020 04:05

Hi I’m considering this stock for my portfolio but still doing my research, I can clearly see they are dedicated to making a real difference. To deliver this alternative therapy for AML following successful trials would indeed be groundbreaking and a biotech like this should be supported. I wish I was in at the first 1.8p placement level or even the more recent 7p level but will likely buy in anyhow simply because “I like what they are doing and the world is better for biotechs like Hemo”. morally it feels right to me to own this stock but I’m not convinced it will deliver a good ROI? If they are just about to go into clinical trials this is going to take some time. Further, will they run out of cash before they can get even close to revenue creation from drug licensing? Does anyone know if another placement is likely? Do we know what the current runway looks like before another cash call and did you need to be an existing shareholder to take advantage of the last share issue? I would value feedback from anyone more clued up on this stock - thanks

[jibba jabber] 17/10/2020 07:18

Yes indeed CD55!

[countdracula55] 16/10/2020 21:42

Timberrrrrrrrrrrrrrrr.

[jibba jabber] 16/10/2020 08:09

I think we will see 11p today.

[dual] 13/10/2020 23:48

Eli Lilly Covid Antibody Trial Paused Due to Safety Concernswww.bloomberg.com/news/articles/2020-10-13/eli-lilly-virus-antibody-trial-paused-due-to-safety-concerns

[jayminpatel1] 13/10/2020 11:24

Down she goes the pump is well and truely over

[jibba jabber] 13/10/2020 10:17

You won't be saying that at £3 you mug.

[tullynessle] 12/10/2020 20:22

The article is too technical for me - it talks about "Immune cell activation in severe COVID-19 resembles lupus". https://www.miragenews.com/immune-cell-activation-in-severe-covid-19-resembles-lupus/ Mirage Immune cell activation in severe COVID-19 resembles lupus OCTOBER 8, 2020 In severe cases of COVID-19, an exuberant activation of immune cells resembles that seen in acute flares of systemic lupus erythematosus (SLE), an autoimmune disease. New research from Emory University School of Medicine points towards tests that could separate some COVID-19 patients who need immune-calming therapies from others who may not. It also may begin to explain why some people infected with SARS-CoV-2 produce abundant antibodies against the virus, yet experience poor outcomes. The results were published online on Oct. 7 in Nature Immunology. The Emory team’s results converge with recent findings by other investigators, who found that high inflammation in COVID-19 may disrupt the formation of germinal centers, structures in lymph nodes where antibody-producing cells are trained. The Emory group observed that B cell activation is moving ahead along an “extrafollicular” pathway outside germinal centers – looking similar to they had observed in SLE. Article continues.......

[tullynessle] 12/10/2020 20:14

May be of general interest to the BB https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery Eli Lilly News Release September 14, 2020 Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial - Study Met Primary Endpoint of Reduction of Time to Recovery - Additional Analyses Ongoing to Understand Other Clinical Outcome Data - Lilly's Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib Continues INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2 included more than 1,000 patients and began on May 8 to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19. Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir. News Release continues.....

[tullynessle] 12/10/2020 20:11

#HEMO IS PROUD TO COLLABORATE WITH #EliLillyCo ........ Twitter - Vladislav Sandler, Hemogenyx https://twitter.com/vmsandler?lang=en [Scroll down to Sept 18] Sept 18, 2020 Vladislav Sandler @vmsandler #HEMO IS PROUD TO COLLABORATE WITH #EliLillyCo Lilly Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

[justtrying1] 12/10/2020 18:22

This dog got left behind in the rampsPmsl

[guss] 08/10/2020 20:40

Ah, world conspiracy and lizard people I expect.

[jibba jabber] 08/10/2020 16:39

The plandemic is the WHO and big pharma plan.

[tullynessle] 08/10/2020 16:26

The Half-year report to 30 June 2020 issued on 30th Sept 2020 reports progress on a number of initiatives. Appears impressive, however I suspect that we need more guidance from Hemogenyx before making any assumptions (guesses) about the progress of current collaborations or the potential for new or expanded activities covered by such relationships. Certainly their "COVID-19 project" and "Autoimmune diseases" work appears topical and important at this time. https://hemogenyx.com/investors/investors/announcements/announcement/2020/half-year-report-interim-results-for-the-period-ended-30-june-2020/ Hemogenyx Pharmaceuticals plc Half-year Report – Interim Results for the Period Ended 30 June 2020 30 Sep 2020 Half-year Report Interim Results for the period ended 30 June 2020 Hemogenyx Pharmaceuticals plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2020. EXTRACT: Interim Management Report Hemogenyx Pharmaceuticals presents an update on the Company’s activities for the six months ended 30 June 2020. Hemogenyx Pharmaceuticals plc is the holding company for Hemogenyx LLC, a US-based biotechnology company developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. These products are: CDX antibodies – CDX bi-specific antibodies for the treatment of AML and conditioning for bone marrow transplants. CDX antibodies act by redirecting a patient’s own immune cells to eliminate unwanted leukaemic and blood stem cells, preparing a patient for bone marrow transplantation; HEMO-CAR-T – CAR-T* cells for the treatment of AML and conditioning for bone marrow transplants; Hu-PHEC – a cell replacement product using Human Postnatal Hemogenic Endothelial Cells to generate cancer-free, patient-matched blood stem cells after transplant into the patient; Anti-SARS-CoV-2 – a neutralising antibody based treatment for COVID-19. *CAR-T therapy is a treatment in which a patient’s own T cells, a type of immune cell, are modified to recognise and kill the patient’s cancer cells. The procedure involves: isolating T cells from the patient; modifying the isolated T cells in a laboratory using a CAR (Chimeric Antigen Receptor) gene construct (which allows the cells to recognise the patient’s cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient. The Company has also developed a platform technology for disease modelling and drug discovery: Advanced Hematopoietic Chimeras (“AHC”) – The Company has developed a new type of humanised mice to advance the development of its CDX antibodies. The unique properties of the AHC give them a functional human immune system that converts them into a platform technology that is opening up exciting opportunities for the Company. These include disease modelling (blood cancers and severe autoimmune diseases) and pre-clinical testing of novel drugs and treatments. AHC are a source of revenue for the Company via paid collaborations with biopharmaceutical companies and research institutions. In addition, the Company’s wholly owned subsidiary Immugenyx, LLC has developed Advanced peripheral blood Hematopoietic Chimeras (“ApbHC”), a novel type of humanised mouse that presents several advantages over other mouse models. Immugenyx was established by the Company to develop and commercialise the Company’s humanised mice, and the new ApbHC represents a significant further development in that direction. To date, Hemogenyx Pharmaceuticals has made impressive progress on its products whilst efficiently using the Company’s limited financial resources. The Company’s main areas of focus are to progress its CDX antibodies to readiness for clinical trials, to advance HEMO-CAR-T through pre-clinical development toward clinical trials, and to develop a novel treatment for COVID-19. H1 progress update During the first half of the year, Hemogenyx Pharmaceuticals made significant progress on several fronts: CAR-T cells Hemogenyx Pharmaceuticals successfully constructed and tested Chimeric Antigen Receptor (CAR) programmed T cells (“HEMO-CAR-T”) for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T was constructed using Hemogenyx Pharmaceuticals’ proprietary humanised monoclonal antibody against a target on the surface of AML cells. The Company has demonstrated that HEMO-CAR-T is able to programme human T cells (convert them into HEMO-CAR-T) to identify and destroy human AML-derived cells in vitro and in vivo. Following the period end, the company entered into a Sponsored Research Agreement with the University of Pennsylvania (“Penn”) designed to advance HEMO-CAR-T toward clinical trials. The agreement is envisaged as the first step of a larger programme that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of AML. Dr Saar Gill, Assistant Professor of Medicine, a hematologist-oncologist physician scientist and Scientific co-Director of the Cell Therapy and Transplantation programme at the University of Pennsylvania, serves as Principal Investigator on behalf of Penn. Dr Gill’s laboratory is part of the Center for Cellular Immunotherapies (“CCI”) whose Director, Dr Carl H. June, conducted pioneering clinical trials of genetically engineered cells including CAR-T cells in patients with HIV and diverse forms of cancer. This work will significantly accelerate the development of the Company’s CAR-T product candidate, putting it on a direct path to clinical trials and a possible new treatment for AML, for which there is currently no real effective treatment. CDX bi-specific antibodies Hemogenyx Pharmaceuticals extended its development agreement with a leading global pharmaceutical company (“GlobalCo”) to finalise manufacturability work and successfully bring its CDX bi-specific antibody to a state of readiness for pre-clinical development. Preliminary discussions regarding a potential licensing deal are continuing with GlobalCo following the extension of the Development Agreement. Humanised mice The collaboration agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the development of a model of systemic lupus erythematosus (SLE) is progressing. Autoimmune diseases The Company entered into a Biological Investigation and Material Supply Agreement with Eli Lilly and Company in June 2020 to perform research and development activities aimed at the discovery and validation of novel materials to be used for the treatment of systemic lupus erythematosus (“Lupus”) and possibly other autoimmune diseases. This work complements the Company’s own development efforts in these areas. COVID-19 project As announced in April 2020, Hemogenyx Pharmaceuticals is deploying its groundbreaking research capabilities and technologies to develop treatments for COVID-19. Using the exceptional characteristics of its ApbHC humanised mice, the Company seeks to discover human neutralising antibodies – antibodies that are typically developed by the human immune system to neutralise invading viral pathogens – that could be used to fight infections of SARS-CoV-2, the virus that causes COVID-19. The Company had already been developing treatments to be deployed against other viral pathogens prior to the onset of COVID-19, both independently and with a number of pharmaceutical company partners. The Company’s ApbHC mice were developed in part as a discovery platform for the development of such treatments. Hemogenyx Pharmaceuticals’ scientists have been transplanting cells from blood samples from convalescent COVID-19 patients into its mice, with the goal of recreating and isolating a set of anti-SARS-CoV-2 virus antibodies. In addition to the COVID-19 work, this initiative aims to demonstrate how the Company’s technology can be deployed rapidly in emergencies in order to discover human neutralising antibodies against a host of viral pathogens, including mutations into possible new strains of COVID-19 and also what infectious disease experts in the bioprotection and biodefence sectors call “Disease X”, meaning as-yet unknown viruses that may break out and that may represent a similar or greater threat than the one presented by COVID-19. Human Postnatal Hemogenic Endothelial Cell (“Hu-PHEC”) cell therapy The Company is developing Hu-PHEC, a cell replacement product candidate that aims to generate cancer-free, patient-matched blood stem cells after transplantation into the patient. A patent application entitled Post-Natal Hemogenic Endothelial Cells and Their Isolation and Use was approved by the United States Patent and Trademark Office and issued on 25 February 2020 as Patent Number 10,570,373. A corresponding patent was granted by the European Patent Office on 13 May 2020 as Patent Number 3068875.

[guss] 08/10/2020 16:24

What is a plandemic? Is it a pandemic for the illiterate?

[tullynessle] 08/10/2020 15:48

(see also posts 2020 & 2022) After their News Release yesterday, Eli Lilly issues a "comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs" this afternoon (Thurs Oct 8). https://uk.advfn.com/stock-market/NYSE/LLY/share-news/Lilly-provides-comprehensive-update-on-progress-of/83425305 Eli Lilly Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs 08/10/2020 3:30pm PR Newswire (Canada) TORONTO, Oct. 8, 2020 /CNW/ - Eli Lilly and Company (NYSE: LLY) yesterday announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild- to moderate COVID-19 – and plans to make these therapies broadly available to patients. The pace of this development program is unprecedented," said Dr. Doron Sagman, Lilly Canada's vice president of R&D and Medical Affairs. Lilly's highly skilled and dedicated scientific teams have made significant advances in a very short period of time. These data offer initial evidence that these antibodies could be an effective treatment for COVID-19 and that they could be available for medical use in the near future." Investors, media and the general public are invited to review a webcast that took place yesterday at noon EDT, where Lilly provided more data and discussion on these programs. The webcast information is available here. Combination therapy clinical trial data Data from a new interim analysis of the BLAZE-1 clinical trial showed that combination therapy with two of Lilly's SARS-CoV-2 neutralizing antibodies reduced viral load, symptoms, and COVID-related hospitalization and ER visits. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555 and LY-CoV016, which bind complementary regions of the SARS-CoV-2 spike protein, for the treatment of symptomatic COVID-19 in the outpatient setting. The combination cohort enrolled recently diagnosed patients with mild- to moderate COVID-19, who were assigned to 2800 mg of each antibody (n=112) or placebo (n=156). The combination therapy significantly reduced viral load at day 11 (p=0.011), meeting the primary endpoint of the study. Most patients, including those receiving placebo, demonstrated near complete viral clearance by day 11. Further, combination treatment reduced viral levels at day 3 (p=0.016) and day 7 (p<0.001)—earlier time points during the course of infection when higher viral loads are typically seen. Combination therapy also significantly reduced the time-weighted average change from baseline from day 1 to 11. An exploratory analysis showed that the proportion of patients with persistent high viral load at day 7 for combination therapy was lower (3.0 percent) versus placebo (20.8 percent), corresponding to a nominal p value of p<0.0001 without multiplicity adjustment. No emergent putative resistance variants have been observed thus far in patients treated with combination therapy. Combination therapy also met prespecified clinical endpoints, including the time-weighted average change from baseline in total symptom score from day 1 to 11 (p=0.009). The improvement in symptoms was observed as early as three days after dosing and was similar in magnitude and timing to improvements previously seen with LY-CoV555 monotherapy. The rate of COVID-related hospitalization and ER visits was lower for patients treated with combination therapy (0.9 percent) versus placebo (5.8 percent), a relative risk reduction of 84.5 percent (p=0.049). This was also similar to observations for LY-CoV555 monotherapy. News Release continues

[fission453] 08/10/2020 15:18

We are climbing like no tomorrow! News has leaked!!!!